Cargando…

Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Can-rong, Yin, Wan-chao, Jiang, Yi, Xu, H. Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771608/
https://www.ncbi.nlm.nih.gov/pubmed/35058587
http://dx.doi.org/10.1038/s41401-021-00851-w
_version_ 1784635645720788992
author Wu, Can-rong
Yin, Wan-chao
Jiang, Yi
Xu, H. Eric
author_facet Wu, Can-rong
Yin, Wan-chao
Jiang, Yi
Xu, H. Eric
author_sort Wu, Can-rong
collection PubMed
description Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus has been greatly enhanced over the past 2 years. Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19. In this review, we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed. We present the examples of structure-based design of Pfizer’s novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck’s nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies.
format Online
Article
Text
id pubmed-8771608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-87716082022-01-20 Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 Wu, Can-rong Yin, Wan-chao Jiang, Yi Xu, H. Eric Acta Pharmacol Sin Review Article Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus has been greatly enhanced over the past 2 years. Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19. In this review, we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed. We present the examples of structure-based design of Pfizer’s novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck’s nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies. Springer Nature Singapore 2022-01-20 2022-12 /pmc/articles/PMC8771608/ /pubmed/35058587 http://dx.doi.org/10.1038/s41401-021-00851-w Text en © The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2022
spellingShingle Review Article
Wu, Can-rong
Yin, Wan-chao
Jiang, Yi
Xu, H. Eric
Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title_full Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title_fullStr Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title_full_unstemmed Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title_short Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
title_sort structure genomics of sars-cov-2 and its omicron variant: drug design templates for covid-19
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771608/
https://www.ncbi.nlm.nih.gov/pubmed/35058587
http://dx.doi.org/10.1038/s41401-021-00851-w
work_keys_str_mv AT wucanrong structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19
AT yinwanchao structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19
AT jiangyi structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19
AT xuheric structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19